查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589575

阿霉素市场：按配方、分销管道和应用划分 - 2025-2030 年全球预测

Doxorubicin Market by Drug Formulation (Doxorubicin Injection, Lyophilized Powder), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

根据预测，2023年阿霉素市值为23.9亿美元，预计到2024年将达到26.5亿美元，复合年增长率为10.82%，到2030年将达到49.2亿美元。

阿霉素是一种化疗药物，属于细胞週期蛋白类药物，主要用于治疗多种癌症类型，包括乳癌、卵巢癌和淋巴瘤等。它在癌症治疗中的重要作用凸显了对有效药物传递和降低心臟毒性的需求，从而推动了对脂质体製剂和标靶治疗方案的研究。在癌症发病率上升和生物技术进步的推动下，癌症治疗市场强劲成长，凸显了开发标靶治疗和毒性较低製剂的巨大机会。新兴市场因医疗基础设施的发展而作为潜在的扩张领域占据重要地位。但市场开拓受到副作用严重、监管要求严格、开发核准成本高等因素制约，部分地区准入和购买受到限制。

主要市场统计
基准年[2023] 23.9亿美元
预测年份 [2024] 26.5亿美元
预测年份 [2030] 49.2亿美元
复合年增长率（%） 10.82%

该行业的创新时机已经成熟，趋势是探索新型药物的联合治疗，以提高疗效并减少副作用。利用奈米技术改进递送系统以增加肿瘤部位的药物浓度，同时降低全身毒性也是一个有前景的研究途径。此外，结合生物标记主导的治疗计划来优化药物疗效的个人化医疗方法也越来越受欢迎。儘管有这些进步的趋势，但学名药药和生物相似药的竞争、分销挑战和智慧财产权障碍等问题仍然是市场快速成长的障碍。

总之，持续的研发投资、开发创新的输送机制以及建立策略伙伴关係对于最大限度地发挥阿霉素的市场潜力至关重要。公司可以考虑专注于精准医疗和联合治疗以脱颖而出。这些进步不仅可以改善治疗结果，还可以提高市场渗透率并使治疗组合多样化，以有效应对竞争格局。这些策略，加上解决监管和成本挑战，可能会重新定义阿霉素市场的业务成长前景。

市场动态：揭示快速发展的阿霉素市场的关键市场洞察

阿霉素市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球癌症发生率增加
    • 政府核准使用阿霉素治疗某些疾病
    • 加大力度提高意识和药物供应
  • 市场限制因素
    • 法律规范的变化
  • 市场机会
    • 持续研发以发现及开发新药
    • 政府对癌症治疗和预防的支持
  • 市场问题
    • 药物的严重副作用

波特的五力：驾驭阿霉素市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解阿霉素市场的外部影响

外部宏观环境因素在塑造阿霉素市场的表现动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解阿霉素市场的竞争格局

对多柔比星市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来发现自己的竞争定位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：阿霉素市场供应商的绩效评估

FPNV定位矩阵是评估阿霉素市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：规划阿霉素市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对阿霉素市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症发生率上升
      • 政府核准使用阿霉素治疗某些疾病
      • 加强努力提高认识并改善药物可得性
    • 抑制因素
      • 法规结构的变化
    • 机会
      • 持续研发以发现及开发新药
      • 政府对癌症治疗和预防的支持
    • 任务
      • 药物的严重副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章阿霉素市场：按配方

  • 介绍
  • 阿霉素注射液
  • 冻干粉

第七章阿霉素市场：按分销管道

  • 介绍
  • 医院药房
  • 网路药房
  • 零售药房

第八章阿霉素市场：依应用分类

  • 介绍
  • 骨癌
  • 乳癌
  • 子宫内膜癌
  • 胃癌
  • 卡波西氏肉瘤
  • 肾癌
  • 白血病
  • 肝癌
  • 多发性骨髓瘤
  • 卵巢癌

第9章 美洲阿霉素市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太阿霉素市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲阿霉素市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie, Inc.
  • Cadila Pharmaceuticals Ltd.
  • Changzhou Kinyond Pharmaceutical Co., Ltd
  • Cipla, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Getwell Oncology Pvt Ltd
  • Glenmark Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Limited
  • Ipsen SA
  • Janssen Global Services, LLC By Johnson & Johnson Services, Inc.
  • LGM Pharma, LLC
  • Manus Aktteva Biopharma LLP
  • Meiji Holdings Co., Ltd.
  • Merrimack Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • SRS pharmaceuticals Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals
  • Thymoorgan Pharmazie GmbH
  • TTY Biopharma
Product Code: MRR-ED54C46E8664

The Doxorubicin Market was valued at USD 2.39 billion in 2023, expected to reach USD 2.65 billion in 2024, and is projected to grow at a CAGR of 10.82%, to USD 4.92 billion by 2030.

Doxorubicin, a chemotherapeutic agent, falls within the anthracycline drug class and is utilized primarily for treating several cancer types, notably breast cancer, ovarian cancer, and lymphoma. Its pivotal role in oncology emphasizes the need for efficient drug delivery and reduced cardiotoxicity, bolstering research in liposomal formulations and targeted therapy options. The cancer therapeutics market's robust growth, fueled by increasing cancer prevalence and advancements in biotechnology, highlights noteworthy opportunities in developing targeted and less toxic doxorubicin formulations. Emerging markets, due to evolving healthcare infrastructures, represent significant potential expansion areas. However, market growth is tempered by factors such as significant side effects, stringent regulatory requirements, and high development and approval costs, leading to limited accessibility and affordability in some regions.

KEY MARKET STATISTICS
Base Year [2023] USD 2.39 billion
Estimated Year [2024] USD 2.65 billion
Forecast Year [2030] USD 4.92 billion
CAGR (%) 10.82%

The industry is seeing an inclination toward researching combination therapies where doxorubicin is paired with novel agents to enhance efficacy and reduce adverse reactions, thus presenting an area ripe for innovation. Leveraging nanotechnology to improve delivery systems and diminish systemic toxicity while enhancing drug concentration at tumor sites is another promising research avenue. Additionally, personalized medicine approaches, incorporating biomarker-driven treatment plans to optimize drug efficacy, are gaining traction. Despite these progressive trends, issues like competition from generic alternatives and biosimilars, distribution challenges, and intellectual property hurdles persist as barriers to swift market growth.

In conclusion, the onus lies on continuous R&D investments, innovative delivery mechanism development, and strategic partnerships to unleash doxorubicin's full market potential. Companies can consider focusing on precision medicine and combination therapies to stand out. These advancements can not only enhance therapeutic outcomes but also catalyze market penetration, diversifying therapeutic portfolios to withstand the competitive landscape effectively. Such strategies, coupled with addressing regulatory and cost challenges, could redefine business growth prospects in the doxorubicin market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Doxorubicin Market

The Doxorubicin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing cancer incidence rate worldwide
    • Government approvals for use of doxorubicin against certain disorders
    • Growing effort towards increasing awareness and drug availability
  • Market Restraints
    • Changing regulatory frameworks
  • Market Opportunities
    • Ongoing research and development for novel drug discovery and development
    • Supportive government initiatives for cancer treatment and prevention
  • Market Challenges
    • Serious side effects of the drug

Porter's Five Forces: A Strategic Tool for Navigating the Doxorubicin Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Doxorubicin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Doxorubicin Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Doxorubicin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Doxorubicin Market

A detailed market share analysis in the Doxorubicin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Doxorubicin Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Doxorubicin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Doxorubicin Market

A strategic analysis of the Doxorubicin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Doxorubicin Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Cadila Pharmaceuticals Ltd., Changzhou Kinyond Pharmaceutical Co., Ltd, Cipla, Inc., Dr. Reddy's Laboratories Ltd., Getwell Oncology Pvt Ltd, Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Limited, Ipsen S.A., Janssen Global Services, LLC By Johnson & Johnson Services, Inc., LGM Pharma, LLC, Manus Aktteva Biopharma LLP, Meiji Holdings Co., Ltd., Merrimack Pharmaceuticals, Inc., Novartis AG, Pfizer, Inc., SRS pharmaceuticals Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals, Thymoorgan Pharmazie GmbH, and TTY Biopharma.

Market Segmentation & Coverage

This research report categorizes the Doxorubicin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Formulation, market is studied across Doxorubicin Injection and Lyophilized Powder.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on Application, market is studied across Bone Sarcoma, Breast Cancer, Endometrial Cancer, Gastric Cancer, Kaposi Sarcoma, Kidney Cancer, Leukemia, Liver Cancer, Multiple Myeloma, and Ovarian Cancer.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing cancer incidence rate worldwide
      • 5.1.1.2. Government approvals for use of doxorubicin against certain disorders
      • 5.1.1.3. Growing effort towards increasing awareness and drug availability
    • 5.1.2. Restraints
      • 5.1.2.1. Changing regulatory frameworks
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for novel drug discovery and development
      • 5.1.3.2. Supportive government initiatives for cancer treatment and prevention
    • 5.1.4. Challenges
      • 5.1.4.1. Serious side effects of the drug
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Doxorubicin Market, by Drug Formulation

  • 6.1. Introduction
  • 6.2. Doxorubicin Injection
  • 6.3. Lyophilized Powder

7. Doxorubicin Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Online Pharmacy
  • 7.4. Retail Pharmacy

8. Doxorubicin Market, by Application

  • 8.1. Introduction
  • 8.2. Bone Sarcoma
  • 8.3. Breast Cancer
  • 8.4. Endometrial Cancer
  • 8.5. Gastric Cancer
  • 8.6. Kaposi Sarcoma
  • 8.7. Kidney Cancer
  • 8.8. Leukemia
  • 8.9. Liver Cancer
  • 8.10. Multiple Myeloma
  • 8.11. Ovarian Cancer

9. Americas Doxorubicin Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Doxorubicin Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Doxorubicin Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Cadila Pharmaceuticals Ltd.
  • 3. Changzhou Kinyond Pharmaceutical Co., Ltd
  • 4. Cipla, Inc.
  • 5. Dr. Reddy's Laboratories Ltd.
  • 6. Getwell Oncology Pvt Ltd
  • 7. Glenmark Pharmaceuticals Ltd.
  • 8. Intas Pharmaceuticals Limited
  • 9. Ipsen S.A.
  • 10. Janssen Global Services, LLC By Johnson & Johnson Services, Inc.
  • 11. LGM Pharma, LLC
  • 12. Manus Aktteva Biopharma LLP
  • 13. Meiji Holdings Co., Ltd.
  • 14. Merrimack Pharmaceuticals, Inc.
  • 15. Novartis AG
  • 16. Pfizer, Inc.
  • 17. SRS pharmaceuticals Pvt. Ltd.
  • 18. Sun Pharmaceutical Industries Ltd.
  • 19. Teva Pharmaceuticals
  • 20. Thymoorgan Pharmazie GmbH
  • 21. TTY Biopharma

LIST OF FIGURES

  • FIGURE 1. DOXORUBICIN MARKET RESEARCH PROCESS
  • FIGURE 2. DOXORUBICIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DOXORUBICIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DOXORUBICIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DOXORUBICIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DOXORUBICIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DOXORUBICIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DOXORUBICIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DOXORUBICIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DOXORUBICIN MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DOXORUBICIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DOXORUBICIN MARKET DYNAMICS
  • TABLE 7. GLOBAL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DOXORUBICIN MARKET SIZE, BY DOXORUBICIN INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DOXORUBICIN MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DOXORUBICIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DOXORUBICIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DOXORUBICIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DOXORUBICIN MARKET SIZE, BY BONE SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DOXORUBICIN MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DOXORUBICIN MARKET SIZE, BY ENDOMETRIAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DOXORUBICIN MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DOXORUBICIN MARKET SIZE, BY KAPOSI SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DOXORUBICIN MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DOXORUBICIN MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DOXORUBICIN MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DOXORUBICIN MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DOXORUBICIN MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM DOXORUBICIN MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. DOXORUBICIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 153. DOXORUBICIN MARKET, FPNV POSITIONING MATRIX, 2023